Tuesday, November 13, 2012
FDA Regulators in November approved Pfizer’s Xeljanz treatment for rheumatoid arthritis, which is now poised to compete with Abbott Laboratories’ top-selling Humira. Pfizer’s pill is for patients with moderate to severe rheumatoid arthritis who did not benefit from or were unable to tolerate the standard oral treatment, methotrexate. Xeljanz can be used by itself or in combination with methotrexate and certain other treatments.
The F.D.A. approved a 5-milligram dose of Xeljanz, given twice a day. The agency said further safety data was needed to assess a 10-milligram, twice-daily dose, that Pfizer had also put before regulators.
Read about this in the New York Times online at http://www.nytimes.com/2012/11/07/business/fda-clears-a-pfizer-treatment-for-rheumatoid-arthritis.html?partner=rss&emc=rss&_r=0
William Wombacher, your Central Illinois Certified Elder Law Attorney (CELA) and Social Security Disability Specialist. I'll help you! www..wombacherlaw.com
Serving Peoria, East Peoria, Peoria Heights, Pekin, Dunlap, Chillicothe, Morton, Washington, Metamora, Canton, Galesburg, Bloomington, Normal and surrounding cites and counties of Peoria, Tazewell, Woodford, Fulton and Knox Counties in Central Illinois.